Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
ARS
2022 FY
Annual report to shareholders
2 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
Current reports
8-K
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
27 Mar 24
8-K
Patent for composition of matter and use of Infectimune® based influenza vaccines granted in the United States
13 Mar 24
8-K
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
22 Jan 24
8-K
Other Events
4 Dec 23
8-K
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
28 Nov 23
8-K
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
14 Nov 23
8-K
Other Events
9 Nov 23
8-K
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
23 Oct 23
8-K
Other Events
11 Oct 23
8-K
Other Events
3 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
28 Mar 24
S-8
Registration of securities for employees
14 Nov 23
S-8
Registration of securities for employees
24 Aug 22
S-3
Shelf registration
24 Aug 22
S-8
Registration of securities for employees
1 Apr 22
S-8
Registration of securities for employees
15 Nov 21
424B5
Prospectus supplement for primary offering
16 Jun 21
424B5
Prospectus supplement for primary offering
14 Jun 21
424B2
Prospectus for primary offering
12 Aug 20
424B5
Prospectus supplement for primary offering
10 Aug 20
Proxies
PRE 14A
Preliminary proxy
18 Apr 24
DEFA14A
Additional proxy soliciting materials
2 Jun 23
DEF 14A
Definitive proxy
2 Jun 23
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEFA14A
Additional proxy soliciting materials
3 Jan 22
DEFA14A
Additional proxy soliciting materials
27 Dec 21
DEF 14A
Definitive proxy
16 Dec 21
PRE 14A
Preliminary proxy
30 Nov 21
DEFA14A
Additional proxy soliciting materials
29 Apr 21
Other
EFFECT
Notice of effectiveness
6 Sep 22
CORRESP
Correspondence with SEC
30 Aug 22
UPLOAD
Letter from SEC
29 Aug 22
EFFECT
Notice of effectiveness
3 Aug 20
CORRESP
Correspondence with SEC
29 Jul 20
UPLOAD
Letter from SEC
27 Jul 20
EFFECT
Notice of effectiveness
12 Feb 20
CORRESP
Correspondence with SEC
10 Feb 20
CORRESP
Correspondence with SEC
10 Feb 20
CORRESP
Correspondence with SEC
7 Feb 20